VIVEVE MEDICAL, INC. (NASDAQ:VIVE) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry Into a Material Definitive Agreement.
On December 12, 2017, Viveve Medical, Inc. (the “Company”) entered into a waiver (the “Term Loan Agreement Waiver”) to the Term Loan Agreement, dated May 22, 2017 (as amended by the amendment dated as of November 29, 2017) among CRG Servicing LLC (“CRG”), as administrative agent and collateral agent, the lenders from time to time party thereto and Viveve, Inc., as subsidiary guarantor (the “Term Loan Agreement”). The Term Loan Agreement Waiver (among other things) waives certain conditions to subsequent borrowings under the Term Loan Agreement and permits the Company to borrow up to $10,000,000 (the available amount remaining under the Term Loan Agreement) in a single subsequent borrowing.
On December 12, 2017, the Company delivered a notice of borrowing to CRG requesting a borrowing under the Term Loan Agreement in an amount of $10,000,000 to be funded on or about December 29, 2017.
The foregoing description of the Term Loan Agreement Waiver is qualified in its entirety by reference to the full text of the Term Loan Agreement Waiver, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item 1.01 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 above with respect to the Term Loan Agreement Waiver and subsequent borrowing is incorporated herein by reference.
Item 1.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
10.1 |
Waiver No. 2 to Loan Agreement, dated December 12, 2017, among Viveve Medical, Inc., CRG Servicing LLC and the lenders party thereto. |
VIVEVE MEDICAL, INC. ExhibitEX-10.1 2 ex_102119.htm EXHIBIT 10.1 ex_102119.htm Exhibit 10.1 WAIVER NO. 2 TO LOAN AGREEMENT THIS WAIVER NO. 2 TO LOAN AGREEMENT,…To view the full exhibit click here
About VIVEVE MEDICAL, INC. (NASDAQ:VIVE)
Viveve Medical, Inc., formerly PLC Systems, Inc., designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office. The Viveve System uses monopolar radiofrequency (RF) energy to generate low temperature heat. The vaginal mucosa is simultaneously cooled while this non-ablative heat is delivered into the submucosal layer. The RF energy stimulates the formation of collagen and causes the collagen fibers to remodel thereby tightening the submucosal tissue of the vaginal introitus. The RF stimulation causes subtle alterations in the collagen that can renew the tissue and further tighten the vaginal tissue over the next 1 to 3 months following treatment (the Viveve Treatment) and lead to increased sexual function.